Genenta Science S.p.A. Stock (NASDAQ:GNTA)


Chart

Previous Close

$3.28

52W Range

$2.56 - $7.13

50D Avg

$3.38

200D Avg

$3.83

Market Cap

$60.36M

Avg Vol (3M)

$9.05K

Beta

0.58

Div Yield

-

GNTA Company Profile


Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

IT

Employees

13

IPO Date

Dec 15, 2021

Website

GNTA Performance


Peer Comparison


TickerCompany
PRTCPureTech Health plc
INSMInsmed Incorporated
XOMAXOMA Royalty Corp.
MOLNMolecular Partners AG
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks